Successful treatment of hepatocellular carcinoma with regorafenib after sorafenib-induced hypersensitivity

Naoki Yoshioka, Teiji Kuzuya, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Masatoshi Ishigami, Mitsuhiro Fujishiro

研究成果: Article査読

1 被引用数 (Scopus)

抄録

Sorafenib and regorafenib are tyrosine kinase inhibitors that are used in the treatment of hepatocellular carcinoma and which have similar chemical structures and toxicity profiles. We herein report a case in which regorafenib treatment could be continued for 10 months and stable disease could be maintained for a long period despite the discontinuation of sorafenib due to grade 4 liver injury and grade 3 fever. The severe adverse events could be attributed to drug hypersensitivity, since a drug-induced lymphocyte stimulation test (DLST) indicated sensitivity to sorafenib. A DLST for regorafenib was negative. This is the first report showing that regorafenib could be safely administered after the discontinuation of sorafenib due to hypersensitivity.

本文言語English
ページ(範囲)2803-2808
ページ数6
ジャーナルInternal Medicine
58
19
DOI
出版ステータスPublished - 2019
外部発表はい

All Science Journal Classification (ASJC) codes

  • 内科学

フィンガープリント

「Successful treatment of hepatocellular carcinoma with regorafenib after sorafenib-induced hypersensitivity」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル